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Abstract
 
Dendritic cells (DCs) are able in tissue culture to phagocytose and present antigens derived
from infected, malignant, and allogeneic cells. Here we show directly that DCs in situ take up
these types of cells after fluorescent labeling with carboxyfluorescein succinimidyl ester (CFSE)
and injection into mice. The injected cells include syngeneic splenocytes and tumor cell lines,
induced to undergo apoptosis ex vivo by exposure to osmotic shock, and allogeneic B cells
killed by NK cells in situ. The CFSE-labeled cells in each case are actively endocytosed by DCs
in vivo, but only the CD8
 
 
 
 subset. After uptake, all of the phagocytic CD8
 
 
 
 DCs can form
major histocompatibility complex class II–peptide complexes, as detected with a monoclonal
antibody specific for these complexes. The CD8
 
 
 
 DCs also selectively present cell-associated
antigens to both CD4
 
 
 
 and CD8
 
 
 
 T cells. Similar events take place with cultured DCs; CD8
 
 
 
DCs again selectively take up and present dying cells. In contrast, both CD8
 
 
 
 and CD8
 
 
 
 DCs
phagocytose latex particles in culture, and both DC subsets present soluble ovalbumin captured
in vivo. Therefore CD8
 
 
 
 DCs are specialized to capture dying cells, and this helps to explain
their selective ability to cross present cellular antigens to both CD4
 
 
 
 and CD8
 
 
 
 T cells.
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Introduction
 
Dendritic cells (DCs)
 
*
 
 are particularly efficient in the cross
presentation of antigens. DCs can present, on MHC class I
products, peptides derived from incoming immune com-
plexes (1–3), heat shock proteins (4–6), nonreplicating bac-
teria (7), and dying cells (8–13). Dying cells are likely to be
an important source of antigen in many settings, for exam-
 
ple, tumors, transplants, infections, and autoimmunity. To
understand the role of DCs in the presentation of cell-associ-
ated antigens, which occurs efficiently on both MHC class
I (8–13) and class II products (14, 15), we have directly
followed the capacity of DCs to take up dying cells in
 
vivo, particularly spleen cells labeled with carboxyfluo-
rescein succinimidyl ester (CFSE). Injected splenocytes are
commonly used to follow the immune response to cell
associated antigens (16–18), and DCs are the principal cells
presenting these antigens onto MHC class I (19). We find
that uptake of several types of dying cells in situ occurs se-
lectively in the CD8
 
 
 
 subset of DCs. This is associated
with selective presentation on both MHC class I and II
products. In contrast, uptake of latex occurs to a compara-
ble extent in both CD8
 
 
 
 and CD8
 
 
 
 DCs as reported (20).
We discuss the emerging evidence that subsets of DCs have
distinct endocytic receptors, a critical limiting variable for
implementing antigen presentation, and that one potential
consequence of apoptotic cell uptake is tolerance to cell
associated antigens.
 
Materials and Methods
 
Mice.
 
C57BL/6, (BALB/c 
 
 
 
 DBA/2) F
 
1
 
 (CD2F
 
1
 
), CBA/J,
and BALB/c mice were purchased from Japan SLC or Nippon
Clea. TCR transgenic mice were specific for OVA presented on
H-2K
 
b
 
 or I-A
 
b
 
 (CD8
 
 
 
 OT-I and CD4
 
 
 
 OT-II; provided by Dr.
F. Carbone, University of Melbourne, Parkville, Victoria, Aus-
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tralia) or specific for I-E presented on I-A
 
b
 
 (CD4
 
 
 
 1H3 T cells;
provided by C. Viret and C.A. Janeway, Jr., Yale University,
New Haven, CT). DEC-205 (CD205)-deficient mice were made
and provided by M. Nussenzweig (Rockefeller University, New
York, NY). The mice were maintained under specific pathogen
free conditions and used at 7–8 wk of age. All experiments were
conducted according to institutional guidelines.
 
Antibodies and Reagents.
 
Rat mAbs for MHC class II
(TIB120, M5/114.15.2), CD205 (HB290, DEC-205), granulo-
cytes (RB6–8C5: Gr-1), B220 (TIB146: RA3–3A1, RA3–6B2),
F4/80 (HB198), and CD8 (TIB211, 3.155) were from American
Type Culture Collection. FITC-anti-CD11c, CD3
 
 
 
, Thy-1.2
(CD90), B220 and CD107b, PE-conjugated anti-CD8
 
 
 
, CD11b,
CD11c, biotinylated anti-CD4, CD8
 
 
 
, I-A
 
b
 
, CD40, CD54, CD80,
CD86 and CD11c, mouse anti–human V
 
 
 
8, and streptavidin-
CyChrome
 
®
 
 were from BD PharMingen. Y-Ae mAb, specific
for the MHC–peptide complex formed by I-A
 
b
 
 presenting a pep-
tide from I-E (14, 21), was provided by Dr. C.A. Janeway, Jr.
Anti-CD11c, CD43, CD19, and CD5 microbeads
 
®
 
 were from
Miltenyi Biotec. The other reagents were rat IgG, FITC-conju-
gated mouse anti–rat IgG, biotin-conjugated rat IgG, biotin-
conjugated Syrian hamster IgG, Cy3-conjugated F(ab
 
 
 
)
 
2
 
 mouse
anti–rat IgG, Cy3-conjugated F(ab
 
 
 
)
 
2
 
 goat anti–rat IgG, streptavi-
din-Cy5 and streptavidin-Cy-3 (Jackson ImmunoResearch Labo-
ratories), biotin-conjugated anti-CD11b and F4/80 (Caltag
Labs), allophycocyanin (APC)-conjugated anti-CD8
 
 
 
 and CD11b
(eBioscience), collagenase D (Boehringer), Percoll (Amersham
Pharmacia Biotech), RPMI 1640 (Nissui Pharmaceutical Co.
Ltd.), 30% BSA solution (Sigma-Aldrich), and avidin-Red670™
(Life Technologies).
 
Cell Preparations.
 
DCs from spleen and subcutaneous lymph
nodes were positively selected (anti-CD11c microbeads
 
®
 
) from
low density cells as described (22). In some experiments, the
CD8
 
 
 
 
 
 DCs subset was first positively enriched with anti-CD8
microbeads
 
®
 
 from spleen low-density cells, depleted of T cells by
either CD3
 
 
 
 or CD90, B cells by either CD19 or B220, and
granulocytes by Gr-1; then CD8
 
 
 
 
 
, CD11c
 
 
 
 DCs were purified
by anti-CD11c microbeads
 
®
 
 from the remaining cells. In other
experiments, CD8
 
 
 
 and CD8
 
 
 
 DCs were purified by sorting
with EPICS ALTRA
 
®
 
 flow cytometer (Beckman Coulter) after
preenrichment of CD11c
 
 
 
 DCs by Microbeads
 
®
 
. Liver DCs
were prepared from collagenase-digested livers enriched for leu-
kocytes on Percoll gradients, followed by the depletion of CD3,
B220, and Gr-1-expressing cells as described (23). In liver, low
and high CD11b expression is preferable for identifying DC sub-
sets, because CD8 expression is lower than in spleen (23).
B cells were negatively selected CD43
 
 
 
 cells (anti-CD43 mi-
crobeads
 
®
 
) from spleen suspensions. In some experiments, B cells
were activated with goat F(ab
 
 
 
)
 
2
 
 anti–mouse IgM/IgG plus IL-4
for 2 d as described (14). TCR-transgenic, CD8
 
 
 
 OT-I T cells
were prepared by depleting B220, Gr-1, CD4, F4/80, MHC class
II, and NK1.1-expressing cells using sheep anti–rat IgG Dyna-
beads
 
®
 
. For CD4
 
 
 
 OT-II and 1H3 T cells, anti-CD8 instead of
CD4 mAb was used. Macrophages were peritoneal exudate cells
of mice that had been injected with 2 ml of thioglycollate me-
dium 4 d before.
To label with CFSE (Molecular Probes), B cells or the BaF3
and EL-4 cell lines were suspended at 10
 
7
 
/ml in RPMI and incu-
bated with CFSE at concentrations of 5 
 
 
 
M for in vivo injection
and 1 
 
 
 
M for in vitro assay for 10 min at 37
 
 
 
C. The reaction was
stopped by washing three times with PBS-0.1% BSA. CFSE-
labeled cells were osmotically shocked (16–18) to accelerate apop-
tosis. By this treatment, 55% of the cells were stained with both
 
PI and annexin, and 17% were PI
 
 
 
 and annexin
 
 
 
, within 3 h of
culture at 37
 
 
 
C, whereas only 5 and 6% of untreated cells became
PI
 
 
 
 annexin
 
 
 
 and PI
 
 
 
 annexin
 
 
 
, respectively.
For NK cell depletion, mice were injected intraperitoneally
with 50 
 
 
 
l of rabbit anti–mouse asialo-GM1 serum (Wako Pure
Chemical Industries Ltd.) 3 and 1 d before injecting CFSE-labeled
B cells. Control mice were injected with normal rabbit serum.
 
In Vivo Uptake of FITC-Latex Microspheres or CFSE-labeled Cells
by DCs.
 
Three mice/group were injected with 200 
 
 
 
l of 0.27%
1 
 
 
 
m Fluoresbrite™ Yellow Green Carboxylate Microspheres
(FITC-Lx; Polysciences, Inc.) or 1–2 
 
 
 
 10
 
7
 
 CFSE-labeled cells
intravenously. The mice were killed at various time points, and
FITC- or CFSE-labeled cells were analyzed in the CD11c
 
 
 
 frac-
tion by FACS
 
®
 
, or by deconvolution microscopy (Olympus) af-
ter sorting with an EPICS ALTRA
 
®
 
 flow cytometer as above.
 
In Vitro Uptake of FITC-Latex Microspheres or CFSE-labeled Cells
by DCs.
 
After staining with PE-CD8
 
 
 
 or PE-CD11b mAbs,
enriched CD11c
 
 
 
 DCs at 10
 
5
 
 cells/well were seeded in triplicate
with a final concentration of 0.0027% (vol/vol) FITC-Lx or
graded doses of CFSE-labeled, osmotically shocked B cells in 0.2
ml of RPMI 1640 supplemented with 5% FCS, 50 
 
 
 
M 2-mer-
captoethanol, 100 
 
 
 
g/ml streptomycin, and 100 U/ml penicillin
in 96-well flat-bottomed plates, and then cultured for 1–12 h in a
CO
 
2
 
 incubator. Controls were incubated at 4
 
 
 
C. The percentage
of phagocytic DCs in each subset was calculated by subtracting
the value of the control from the experimental culture.
 
Flow Cytometric Analyses.
 
Low density spleen, lymph node,
and liver leukocytes were depleted of CD3
 
 
 
, Gr-1, and B220-
expressing cells and stained with PE-CD11c in combination with
biotinylated mAbs plus streptavidin-Red670 or -CyChrome
 
®
 
.
Cells were incubated before staining with 2.4G2 mAb on ice for
30 min to prevent nonspecific mAb binding. All procedures were
performed using cold PBS containing 5 mM EDTA, 0.02%
NaN
 
3
 
, and 1% FCS. DCs were acquired as CD11c
 
 
 
 cells. Surface
antigen expression was monitored on a FACSCalibur™ and ana-
lyzed with CELLQuest™ program (Becton Dickinson) or Win-
MDI software (TSRI). For cytoplasmic staining, the cells stained
with PE-CD11c were fixed with 4% (wt/vol) paraformaldehyde
for 30 min on ice, permeabilized with 0.1% saponin, and incu-
bated with biotinylated mAbs and Avidine-Red 670. For 4-color
staining, the cells were stained with PE-CD11c and APC-CD8
 
 
 
followed by biotinylated mAbs and Streptavidin-CyChrome
 
®
 
.
 
Immunofluorescence Microscopy.
 
Spleen samples were embed-
ded in Tissue-Tek
 
®
 
 OTC (Sakura Fine Technical Co., Ltd.) and
stored at –20
 
 
 
 until use. Cryosections at 10 
 
 
 
m of thickness were
fixed with acetone for 10 min, and then incubated successively
with SER-4 anti-CD169, Cy3-conjugated F(ab
 
 
 
)
 
2
 
 mouse anti–rat
IgG, rat IgG for blocking, biotin-CD11c or CD8
 
 
 
, and strepta-
vidin-Cy5. Purified DCs were adhered to poly-
 
l
 
-lysine-coated
glass coverslips for 1 h in a CO
 
2
 
 incubator. The cells were then
fixed in 3% (wt/vol) paraformaldehyde followed by permeabili-
zation with 0.05% saponin in RPMI 1640 containing 10 mM
HEPES and 10% FCS, and then stained for CD205 or CD107b
using Cy5-conjugated F(ab
 
 
 
)
 
2
 
 mouse anti–rat IgG followed by
biotin-anti-I-A
 
b
 
 and streptavidin-Cy3. After washing, specimens
were mounted with glycerin-PBS (1:1) containing 1% propylgal-
late (Wako Pure Chemicals Industries, Ltd.)
 
Stimulation of TCR Transgenic T Cells to Monitor Antigen Presen-
tation.
 
The experiments used mice injected with C57BL/6
splenocytes or EL-4 tumor cells that had been osmotically
shocked in 10 mg/ml OVA, or mice injected with I-E
 
  alloge-
neic BALB/c B cells. After allowing uptake to take place in situ,
the DCs were added to T cells from TCR transgenic mice1291 Iyoda et al.
(above) to assess presentation of the captured and processed anti-
gens (see legends).
Reverse Transcription PCR. Total RNA was extracted from 106
sorted CD8  and CD8  spleen DCs and peritoneal macrophages
using TRIzol Reagent (GIBCO BRL) and used to produce
cDNA template with SuperScript II (GIBCO BRL) in accor-
dance with manufacturer’s protocols. The cDNA was then used
in reverse transcription (RT)-PCR with Z-Taq DNA poly-
merase (Takara Shuzo). The primers were: for integrin  v (5 -
CAA GCT CAC TCC CAT CAC-3 , 5 -GGG TGT CTT
GAT TCT CAA AGG G-3 ), integrin  3 (5 -TTG CTA CTC
TGC TCA TCT GGA AGC-3 , 5 -TCC CCA CAC TCG
TCA CAC ACA TAAG-3 ), integrin  5A (5 -TTG CCA AGT
TCC AAA GTG A-3 , 5 -GCG TGA CCT TTT TAT TTC
AT-3 ), integrin  5B (5 -TGC CAA GTT CCA AAG CCT-3 ,
5 -GCG TGA CCT TTT TAT TTC AT-3 ), CD14 (5 -TTT
TGG ACT CTG AAT CCC ACT CGG-3 , 5 -TAC CCA
CTG AAC CAT CTT GAC TGC C-3 ), CD36 (5 -CAG CCC
AAT GGA GCC ATC-3 , 5 -CAG CGT AGA TAG ACC
TGC-3 ), scavenger receptor class BI (5 -CAT CTG GTG GAC
AAA TGG AAC G-3 , 5 -CGT GGG AAT GCC TTC AAA
CAC-3 ), macrophage scavenger receptor type I (SR-AI; 5 -
ACA GTT CGA CTG GTT GGT GGT AGT G-3 , 5 -TGA
AGT ACA AGT GAC CCC AGC ATC-3 ), macrophage scav-
enger receptor type II (SR-AII; 5 -CAC CTC TGG ACA AGT
CAT CAA CAC-3 , 5 -GAA GGC AGG AAC ATC CCT
CTA CTC-3 ), C1q receptor (5 -GAC ACC TCA CCC CAG
CCA TCT G-3 , 5 -CAC TGA GTG GTA CAG AAT GGC
AC-3 ), phosphatidylserine receptor (PtdsR; 5 -CAT CAA GGT
GAC CCG AGA AGA AGG-3 , 5 -AAG TTG GTG CTG
CTG GCA AAG TTC-3 ), CD68 (5 -ATG CGG CTC CCT
GTG TGT C-3 , 5 -TCA GAG GGG CTG GTA GGT TG-
3 ), CD4 (5 -GAG AGT CAG CGG AGT TCT C-3 , 5 -CTC
ACA GGT CAA AGT ATT GTT G-3 ), CD23 (5 -GGA
ACTG CAT GCA ACA TAT GTC CCA AGA ACT GGCT-
3 , 5 -GTC AGG GTT CAC TTT TTG GGG TGG GCC T-3 ),
mDC-SIGN (5 -ACA TGA GTG ATT CTA AGG AAA TGG-
3 , 5 -TGT CAA GGT TAT CAA TGG TCA CAG-3 ), and
actin (5 -CAG GAG ATG GCC ACT GCC GCA-3 , 5 -CTC
CTT CTG CAT CCT GTC AGC A-3 ). Amplification was be-
gun at 95 C for 2 min followed by 30 cycles (each cycle being
98 C for 1 s, 60 C for 5 s but 68 C for  -actin, and 72 C for 5 s)
and a final extension of 70 C for 7 min.
Results
Both CD8  and CD8  splenic DCs phagocytose latex in
vivo, but only CD8  DCs take up injected apoptotic sple-
nocytes. Following on the work of Shortman and col-
leagues that splenic DCs phagocytose latex beads adminis-
tered intravenously (20), we injected mice with either 1
micron FITC-modified latex spheres or CFSE-labeled
splenocytes. The latter were subject to osmotic shock,
which is used to load splenocytes with exogenous proteins
like OVA (16–18). We found that apoptosis, as assessed by
FITC-annexin staining, was induced in the majority of
splenocytes within 3 h of an osmotic shock delivered ex
vivo (not shown). 1 h after injecting CFSE-labeled osmoti-
cally shocked splenocytes, or FITC-latex, we enriched
DCs from the spleens on the basis of their low buoyant
density (22). Then flow cytometry with antibodies to
CD11c and CD8 was used to identify the low density cells
that had taken up CFSE-splenocytes or FITC-latex.
Fig. 1 A (left) shows that both CD8  and CD8  DCs
took up latex as described (20), primarily one bead but
occasionally two beads per cell (arrows). However only
CD8  cells endocytosed CFSE-labeled apoptotic spleno-
cytes, either syngeneic or allogeneic (arrows, Fig. 1 A
right). Very few CFSE-labeled cells were noted in the
CD11c  low density cells, or the high density fraction (not
shown), and these were not further characterized. Fig. 1 B
describes the phenotype of the phagocytic DCs in the
CD11c  low density population. Staining for the lysosomal
marker lamp 2 (CD107b) was weak, in contrast to mac-
rophages. The CD68 and 2A1 antigens, found within small
numbers of endocytic vacuoles of DCs (24), were expressed
by phagocytic DCs, but the MIDC-8 marker of T cell area
DCs (25) was lacking. In the case of latex, only some of the
phagocytic cells expressed DEC-205/CD205; however, the
DCs capturing apoptotic splenocytes had a high level of
DEC-205 (Fig. 2 B) and low levels of CD11b (not shown),
as expected for the CD8  subset (26, 27). Therefore, up-
take of particulates in vivo by splenic DCs is influenced by
the particle. Only CD8  DCs take up apoptotic spleno-
cytes, whereas both CD8  and CD8  DCs take up latex.
Selective Uptake of Allogeneic B Cells, Killed by Recipient
NK Cells, by CD8  DCs. Fig. 2 compares the uptake in
vivo of live syngeneic versus allogeneic CFSE-labeled B
cells by C57BL/6 splenic DCs. CD43-negative resting B
cells were used instead of splenocytes to avoid the induc-
tion of graft versus host disease by allogeneic T cells. The
injected cells, which labeled at a high level for CFSE (Fig. 2
A, white arrows), carried B cell markers and were abundant
in the DC-depleted high density population of spleen (not
shown). Fig. 2 A (middle) shows that syngeneic live cells
were for the most part ignored, but allogeneic cells were
again captured by CD8  DCs (Fig. 2 B, black arrowhead).
Fig. 2 B (arrows) shows that CFSE-labeled allogeneic B
cells were captured by the CD8  subset of DCs in spleen,
lymph node, and liver. The kinetics of uptake of CFSE-
labeled cells were then followed using both live and apop-
totic (osmotic shock) allogeneic B cells. DC uptake of live
cells increased with time, so that at 12 h, 20–30% of the
splenic and lymph node DCs had strong CFSE labeling
(Fig. 2 C, filled symbols). In contrast, if apoptotic cells were
injected, the kinetics of uptake were different. The DCs
from spleen and liver became labeled within an hour, but
labeling was decreased at later time points and no labeling
was found in lymph node DCs (Fig. 2 C, open symbols).
These findings raised the hypothesis that the allogeneic B
cells were being killed before efficient uptake by DCs in all
organs through which the B cells were recirculating.
Fossum et al. had years ago described the rapid clearance
of allogeneic leukocytes after NK dependent killing in vivo
and had visualized uptake of injected cell fragments by DCs
in tissue sections through the T cell areas (28). The lytic ac-
tivity of NK cells is activated by “missing self” (29), as
would occur when allogeneic B cells lacking “self MHC”
are injected. We tested if treatment of recipient mice with1292 Uptake of Dying Cells by CD8  DCs In Situ
Figure 1. Apoptotic B cells
and splenocytes, but not FITC-
latex spheres, are selectively cap-
tured by CD8  splenic DCs in
vivo. (A) Groups of three mice
were injected with PBS, FITC-
latex (0.2 ml of a 0.27% solu-
tion), or 20   106 apoptotic
CFSE-labeled syngeneic or allo-
geneic B cells. 1 h later, splenic
suspensions were floated in dense
BSA to provide DC-enriched
low density cells (reference 22).
The latter were stained for
CD11c and CD8 and examined
by FACS® (see also Fig. 2 A).
Shown here are cells gated for
CD11c expression and analyzed
for PE–anti-CD8 and fluores-
cein stain. Phagocytic DCs are
arrowed. The percentage of
phagocytic CD8  and CD8 
DCs for FITC-Lx was 2.7 and
3.8% of total CD11c  cells, re-
spectively. Comparable percent-
ages (1.5%) of DCs were capable
of phagocytosing apoptotic syn-
geneic and allogeneic B cells.
(B) DCs that phagocytose
FITC-latex (5.7%) and CFSE-apoptotic splenocytes (1.45%) are comparable in phenotype (panel numbers are mean fluorescence in arbitrary units), ex-
cept for higher DEC-205 endocytic receptor on those DCs taking up splenocytes (lower right).
Figure 2. Allogeneic B cells are selectively captured by CD8  splenic DCs. (A) Dot plots of the low density spleen population 12 h after injecting mice
with PBS or 20   106 live syngeneic or allogeneic B cells. In the left vertical column, CD11c  DCs are arrowed and contain CD8  and CD8  subsets.
In the right vertical column, the uptake of allogeneic B cells by CD8  DCs is evident (black arrowhead), as are some of the injected strongly CFSE-pos-
itive living B cells (white arrows). 1.3% of low density cells were phagocytic for allogeneic B cells. (B) Uptake of CFSE-labeled allogeneic B cells by
CD8  DCs from spleen and subcutaneous lymph nodes, and CD11b low liver DCs (reference 23), 12 h after injection. Panels of dot plot showed
CD11c  cells, and phagocytic cells in spleen, lymph nodes, and liver were 4.5, 6.6, and 2.5%, respectively. (C) Kinetics of uptake of allogeneic live B
cells, or apoptotic osmotically shocked B cells, by DCs in three organs. Uptake at early time points may result from B cell killing in blood, and at later
time points, killing of B cells within lymphoid tissues in which the B cells recirculate. The percentage of phagocytic DCs are shown for CD8  DCs in
spleen and lymph nodes and CD11blow cells in liver.1293 Iyoda et al.
the NK depleting asialoGM antibody (30, 31) would block
the uptake of CFSE-labeled allogeneic splenocytes by DCs.
The anti-asialoGM antibody did not deplete T cells or B
cells, but splenic CD3  NK-1.1  cells were reduced from
3–4% to  0.1% by this treatment (data not shown). The
treatment nullified the capacity of DCs in spleen and
lymph node to capture injected allogeneic splenocytes (Fig.
3, A and B). As expected for NK-mediated killing, semial-
logeneic B cells were captured much less efficiently than
fully allogeneic ones (Fig. 3 B). Therefore, live allogeneic
cells, probably after killing by NK cells, were efficiently
phagocytosed by CD8  DCs; this provided an efficient
model to further characterize DCs that take up cell associ-
ated antigens in situ.
Identification of Phagocytic DCs in Sections of Spleen. We
first looked in sections for the injected live, CFSE-labeled
allogeneic B cells. Most were found in the B cell areas (fol-
licles) of spleen white pulp and lymph node, as expected
(Fig. 4 A). We occasionally detected cells taking up CFSE-
labeled cells within numerous macrophages of the marginal
zone, but we readily found CFSE-phagosomes within
CD11c  DCs in the T cell areas as well as the red pulp re-
gion (Fig. 4, B and C; white arrows). In contrast, when
FITC latex was injected, we observed extensive uptake at
1 h into CD8 CD11c  DCs in the red pulp (Fig. 4, D and
E, white arrows), CD169  (sialoadhesin ) marginal zone
metallophil macrophages (Fig. 4 E, white arrowheads), as
well as CD169  or low marginal zone macrophages (Fig. 4, D
and E; white arrows). By 3 d, FITC-latex remained abun-
dant in the marginal zone phagocytes, but now DCs
(CD11c , not shown) were noted in the T cell areas (Fig. 4
F, arrow). When apoptotic (osmotically shocked) spleno-
cytes were injected, uptake into CD8  and CD11c  DCs
was prominent in the red pulp (Fig. 4, H and I, white ar-
rows) and also noted in CD169  macrophages of the mar-
ginal zone (Fig. 4, H and I). Therefore, uptake of B cells
killed by NK cells in vivo is selectively observed in
CD11c  DCs in situ whereas uptake of cells induced to ap-
optose ex vivo is extensive in DCs in the red pulp as well as
some marginal zone macrophages.
CD8  DCs Also Selectively Take Up Apoptotic Tumor Cells
Administered Intravenously. We induced apoptosis of differ-
ent cell lines either by withdrawing an essential cytokine
(nontransformed BaF3 cells; Fig. 5 A), or by applying os-
motic shock or high doses (50–300 Gy) of ionizing irradia-
tion (tumorigenic EL-4 cells, Fig. 5 B). The cell lines were
then injected intravenously, and recipient spleen cells exam-
ined for the capture of CFSE-labeled cells. Again, only the
CD8  DC subset took up the injected cells, and only when
cell death had been initiated ex vivo (arrows, Fig. 5 B). As
DEC-205 is an endocytic receptor expressed at high levels
on CD8  DCs, we also tested uptake in DEC-205 / 
mice. However, no defect was noted in DC phagocytosis in
the absence of DEC-205 (Fig. 5 A). In summary, the CD8 
DC subset selectively captures dying cell lines in vivo.
Single Cell Assays to Verify Formation of MHC–Peptide
Complexes from Phagocytosed Dying Cells In Situ. To mon-
itor the processing of cell-associated antigens into MHC–
peptide complexes, we extended a prior tissue culture study
(14) using the Y-Ae monoclonal antibody that is specific
for I-Ab molecules presenting a peptide from another
MHC product, I-E (21). In keeping with the prior work
(14), CFSE-labeled, allogeneic I-E  B cells from BALB/c
mice were injected into I-Ab C57BL/6 mice. 12 h later,
CD8  and CD11c  DCs contained most of the phagocy-
tosed CFSE labeled cells in the spleen cell suspension (Fig.
6 A), and virtually all the CFSE-labeled DCs stained for
Y-Ae above the background observed with control mouse
IgG (Fig. 6 B, right). Y-Ae staining could not be detected
in mice given syngeneic B cells or no B cells (Fig. 6 B,
right). The phagocytic DCs had higher levels of MHC class
II than the nonphagocytic DCs (mean fluorescence index
of 590.5 vs. 251.3 in Fig. 6 B, bottom row), but this high
MHC class II  subset was clearly evident in the nonphago-
Figure 3. Recipient NK cells
are required for DCs to take up
allogeneic B cells. C57BL6 mice
were treated with control antise-
rum or rabbit anti-asialoGM1,
the latter to deplete NK cells
(references 30 and 31). Then
CSFE-labeled 10   106 alloge-
neic (BALB/C) or syngeneic B
cells (A), or 20   106 alloge-
neic (DBA/2) or semiallogeneic
(C57BL6   DBA/2 F1)(B) were
injected intravenously 12 h later,
low density splenocytes were
isolated, stained for CD11c and
CD8, and the percentage of
CFSE-labeled CD11c  DC sub-
sets (CD8  and CD8  deter-
mined by FACS®.1294 Uptake of Dying Cells by CD8  DCs In Situ
Figure 4. Localization of injected particulates in vivo. (A–C) Sections of spleen were examined 12 h after the injection of CFSE-labeled live allogeneic
B cells. In addition to green label from the CFSE-B cells, primarily in the white pulp (A), the sections were stained with CD11c (red DCs) and SER-4/
CD169 (blue marginal zone macrophages). B and C are enlarged views of several red CD11c  DCs that have captured fragments of the injected B cells
(arrows) in the white pulp (CA, central artery) and red pulp. (D–F) Sections of spleen 1 h (D and E) and 3 d (F) after injection of FITC-latex, showing
strong labeling in marginal zone cells early on (MZ), and by day 3 (arrows), in T cell area DCs. Sections were stained with CD8 (red) and SER-4/CD169
(blue; D) or CD11c (red) and SER-4/CD169 (blue; E). Arrows and arrowheads indicate DCs and marginal zone macrophages engulfing FITC-Lx, re-
spectively. (G and H) Sections of spleen, 1 h after injection of CFSE-labeled apoptotic B cells, were stained with either CD8 (G and H) or CD11c (I; red)
in combination with SER-4/CD169 (blue). In contrast with live B cells, very few CFSE-labeled apoptotic cells reached the T area, and most of them
were phagocytosed by marginal zone metallophils and red pulp DCs.1295 Iyoda et al.
cytic DCs from mice given PBS or syngeneic B cells (Fig. 6
B, top and middle rows), suggesting that a subset of MHC
class II rich DCs were either selectively phagocytic or were
expressing high MHC class II because of continuous pro-
cessing of dying cells in the steady state. We then evaluated
presentation by different subsets of spleen cells of this same
I-Ab/I-E peptide complex to CD4  1H3 TCR transgenic
T cells, which have a similar specificity to the Y-Ae mAb
(32). Again CD8  DCs from either spleen or node selec-
tively presented I-E from dying B cells to MHC class II–
restricted CD4  T cells (Fig. 6 C). Therefore, CD8  DCs
efficiently and selectively process dying allogeneic B cells in
situ including for presentation to CD4  T cells.
In Vitro, CD8  DCs Also Selectively Take Up and Present
Antigens from Dying Cells. The selective role of CD8 
DCs in the uptake of dying cells could conceivably relate to
preferential access of dying cells to this subset in vivo. We
therefore performed experiments where apoptotic cells
were fed to CD11c  selected DCs in vitro. Apoptotic syn-
geneic or allogeneic splenocytes were again efficiently cap-
tured by CD8  DCs, but not by CD8  DCs, from spleen,
subcutaneous lymph nodes, and liver (Fig. 7 A). The uptake
of apoptotic cells reached a plateau over 4–12 h (Fig. 7 B).
The percentage of phagocytic CD8  DCs increased with
increasing numbers of administered B cells, so that 60% of
the CD8  DCs showed phagocytic activity at the highest
dose of B cells tested (Fig. 7 C). When we examined the
cells by confocal microscopy, the DEC-205  DCs con-
tained phagosomes with CFSE-labeled fragments (Fig. 7 D),
which is very similar to what we observed if we examined
DCs that had taken up dying cells in vivo (e.g., Fig. 4, B
and C). Both CD8  and CD8  DCs captured FITC latex
in vitro (Fig. 7 E), indicating that CD8  DCs were capable
of phagocytic activity. To verify that the selective uptake of
dying cells was associated with selective cross presentation
of antigen, we fed the DCs splenocytes shocked in the pres-
ence of OVA. The CD8  and CD8  DC subsets were then
added to OVA-specific, MHC class I–restricted, OT-I
TCR transgenic T cells. The CD8  DCs were markedly
enriched in presenting activity (Fig. 7 F). Therefore CD8 
DCs are specialized to take up and cross present dying cells.
In Vivo, CD8  DCs Selectively Capture Antigens from
Dying Cells for Presentation on Both MHC Class I and II Prod-
ucts. It has been reported that CD8  DCs in vivo selec-
tively cross present OVA to OT-I T cells (19). Our find-
ings suggest that this reflects selective uptake of dying
OVA-bearing splenocytes, rather than selective cross pre-
senting function after uptake. To evaluate this, we injected
OVA-shocked splenocytes, isolated CD8  and CD8  DCs
(as well as lymphocytes), and tested if the APCs would
stimulate OT-I and also MHC class II–restricted OT-II T
cells. In fact, the CD8  DCs selectively presented cell-
associated OVA to both CD8  and CD4  T cells (Fig. 8
A). As a positive control for the antigen-capturing activity
of CD8  DCs, we tested for presentation of soluble OVA
protein added to DC–T cell cocultures. Both CD8  and
CD8  DCs presented protein to MHC class II–restricted,
OT-II transgenic T cells but the presentation to OT-I was
weak, as expected for antigens administered in relatively
low doses as a soluble protein (Fig. 8 A, right part of each
panel). To determine if OVA protein injected in vivo
could be presented by both CD8  and CD8  DCs, we
used a high dose, 3 mg, intravenously. Both DC subsets
were able to stimulate MHC class I and class II–restricted
T cells (Fig. 8 B). We conclude that CD8  DCs selec-
tively present antigens from dying cells on both MHC
class I and II products because of their selective endocytic
capacity for dying cells, but that CD8  DCs have the ca-
pacity to present the same protein when taken up by other
endocytic routes.
Expression of mRNA for Different Candidate Receptors for
Dying Cells. A number of receptors have been implicated
in the uptake of dying cells (33, 34), so we used RT-PCR
to search for these in CD8  and CD8  DCs as well as peri-
toneal macrophages. Two of these receptors, SR-AI and
C1qR, were restricted to macrophages, whereas others
(phosphatidyl serine receptor,  5A and B integrins, SR-BI,
CD14, CD68) were found in all three cell types. SR-AII,
Figure 5. CFSE-labeled, cell lines and tumor cells are
selectively captured by CD8 CD11c  DCs in vivo. (A)
20   106 BaF3 tumor cells, induced to apoptose by 12 h of
culture in the absence of IL-3, were injected intravenously;
then splenic DCs were examined 2 h later for CFSE-
uptake (arrows) as in Fig. 1. The experiments were done
in parallel in wild type and DEC-205 /  mice. Phagocytic
DCs in the CD11c  population were 6.3% for C57BL/6
mice and 5.0% in DEC-205 /  mice. (B) 5   106 EL-4
thymoma cells, untreated or induced to apoptose by heavy
irradiation (50 Gy) or by osmotic shock, were injected in-
travenously 2 h later, CD11c  splenocytes were examined
for uptake of CFSE-labeled cells (arrows). CSFE-labeled
DCs were 0.04% in mice injected with untreated cells,
3.1% after osmotically shocked cells, and 5.15% after irra-
diated cells.1296 Uptake of Dying Cells by CD8  DCs In Situ
 v,  3, mDC-SIGN, and CD23 were all more abundant in
CD8  versus CD8  DCs. Only CD36 was more abundant
in CD8  versus CD8  DCs. Therefore this preliminary
analysis only identified CD36 as a possible receptor that se-
lectively guides dying cells to one DC subset, but further
analyses are required.
Discussion
We have followed the uptake of dying cells in vivo, an
event that may be critical for the presentation of cell associ-
ated antigens in many clinical settings. We find that DCs
endocytose dying cells, by directly monitoring the capture
of fluorescein-labeled lymphocytes and various cell lines.
Figure 6. Processing of allogeneic B cells in situ
to form MHC class II-peptide complexes. 20   106
live allogeneic (BALB/C) I-E  B cells, or C57BL/6
syngeneic control B cells, were injected intrave-
nously into C57BL/6 mice. (A) In vivo uptake of
apoptotic B cells (green) by MHC class II  (blue)
and CD107b  (red) DCs. Sorted CFSE-labeled
cells were placed on coverslips, fixed, and stained
with mAbs. (B) Phenotype of CD8  DCs 12 h af-
ter injecting live CFSE labeled allogeneic B cells.
Low density spleen cells, gated for both CD11c and
CD8 expression, were assessed for CFSE uptake (y-
axis) and surface markers (x-axis; see text) including
Y-Ae an epitope formed by I-Ab presenting I-E
peptide. CFSE-labeled DCs by the injection of
syngeneic and allogeneic B cells were 1.38 and
28.1% in CD8  DCs, respectively. (C) At 12 h af-
ter injection of live syngeneic or allogeneic B cells,
low density spleen cells were separated into
CD11c  DCs from the cells depleting CD3 ,
CD90, Gr-1, and B220-expressing cells with anti-
CD11c microbeads. The CD11c  DCs from spleen
and lymph nodes were separated into CD8  and
CD8  subsets by sorting on a FACS Vantage™.
Graded doses were added to 2   105 CD4  1H3
TCR transgenic cells (reference 32) specific for I-Ab
presenting I-E peptide, kindly provided by Drs. C.
Viret and C. Janeway of Yale Medical School,
New Haven, CT. Proliferation ([3H]thymidine up-
take) was measured at 27–40 h.1297 Iyoda et al.
Uptake however takes place primarily in the CD8  subset
of DCs. Likewise, when experiments are performed in
vitro under more easily controlled conditions, the majority
of the CD8  DCs selectively express phagocytic activity
for dying cells. We also find that the selective presenting
activity of CD8  DCs extends to both MHC class I and II
products, whereas both CD8  and CD8  DC subsets are
able to present soluble protein captured in vivo on MHC
Figure 7. CD8  DCs selectively cap-
ture and present dying cells in vitro. (A)
CD11c  DCs were selected were
stained with PE-CD8 for spleen and
subcutaneous lymph nodes and PE-
CD11b for liver. In flat-bottomed mi-
crotest wells, 105 DCs were cocultured
with 3   105 CFSE-labeled apoptotic
(osmotic shock) B cells for 4 h at 4 C or
37 C. Residual B cells were gated from
these FACS® plots by CD19 labeling (bi-
otin-CD19 and avidine-CyChrome®).
(B) Kinetics of uptake (FACS® assay) of
osmotically shocked apoptotic syngeneic
and allogeneic B cells by DCs from
spleen, subcutaneous lymph nodes, and
liver. The percentage of CFSE-labeled
DCs were shown in the respective sub-
sets. (C) Effect of increasing dose of B
cells on the frequency of DCs phago-
cytic for apoptotic B cells. CFSE-labeled
DCs were assessed 4h after coculture as
described in panel A. (D) In vitro uptake
of apoptotic B cells (green) by MHC
class II  (blue) and DEC-205  (red)
DCs. (E) Uptake of FITC latex by DCs
from the three different tissues we have
studied, showing uptake at 37 C (right
side of each panel) by both CD8  and
CD8  DCs. The percentage of FITC-
Lx  CD8  and CD8  DCs and FITC-
Lx  CD8  and CD8  DCs were 33.2,
64.8, 0.7, and 1.3 at 4 C and 28.5, 54.3,
5.3, and 11.9 at 37 C for spleen, 39.4,
52.5, 1.2, and 1.9 at 4 C and 32.7, 46.2,
7.6, and 13.5 at 37 C for subcutaneous
lymph nodes, and those of FITC-Lx 
CD11b  and CD11b  DCs and FITC-
Lx CD11b  and CD11b  DCs were
20.5, 78.0, 0.3, 1.2 at 4 C and 14.1,
60.2, 6.2, and 19.5 at 37 C for liver. (F)
Selective presentation by CD8  DCs of
OVA from apoptotic splenocytes. DCs
were selected from CD3 , Gr-1, and
B220-negative low density splenocytes
sequentially with anti-CD8 and anti-
CD11c microbeads® and cultured for 4 h
with splenocytes (1 DC:3 spleen cells) loaded with 10 mg/ml OVA during osmotic shock.
After the culture, the both subsets of DCs were again stained with FITC-anti-CD11c and
anti-FITC microbeads®, and the DCs were selected by MACS columns to avoid contam-
ination of dead cells. Both CD8  and CD8  subsets were used in graded doses to present
antigen to 2   105 purified OT-I T cells in flat bottomed microtest wells. [3H]thymidine
uptake was measured at 38–50 h.1298 Uptake of Dying Cells by CD8  DCs In Situ
class I and II. These results likely explain the fact that
CD8  DCs selectively cross present cell-associated antigens
(19; Fig. 8). Our findings provide a means for experimen-
tally loading DCs in situ with antigens derived from self, al-
logeneic, or malignant cells (Figs. 1–5).
The capacity of CD8  DCs to take up dying cells is effi-
cient. In the case of allogeneic B cells as substrate, a sub-
stantial proportion of the DCs can be directly visualized
with phagocytosed dying cells by FACS® and by immuno-
fluorescence microscopy in section (Fig. 4 B). If DCs are
isolated after uptake of dying cells in vivo (not shown) or
in vitro (Fig. 7 D), the cells contain several intracellular
CFSE-labeled phagosomes. Furthermore, most of the
phagocytic DCs can be shown to be forming MHC–pep-
tide complexes after processing of a membrane protein from
the dying cells (Fig. 6 B). Uptake of osmotically shocked
Figure 8. CD8  DCs selectively capture dying cells in
vivo for presentation on MHC class I and II products. (A)
OVA presentation from TAP /  splenocytes, osmotically
shocked in PBS or 10 mg/ml OVA (x-axis) before inject-
ing 20   106 cells intravenously per mouse. 4 h later,
spleen cell suspensions were prepared and DCs partially
enriched by flotation in dense BSA solution (reference 22).
Subsets of APCs were isolated by the following sequence
using antibody-coated magnetic beads: mixtures of CD5 
and CD19  cells (B and T), CD8  cells (DCs), and
CD11c  cells (CD8  DCs). Cells were added in graded
doses to 2   105 purified OT-I or OT-II cells in flat-
bottomed microtest wells. Proliferation was measured at
38–50 h, with the data shown for the top dose of APCs
(3   104 for DCs and 2.5   105 for lymphocytes). In par-
allel, cells from the PBS-injected mice were also used to
present OVA protein, at a dose of 30  g/ml continuously
in the DC–T cell cocultures. (B) Both CD8  and CD8 
DCs can present soluble OVA via the exogenous pathway
to MHC class I. Mice were injected intravenously with 3
mg of OVA protein. At the indicated times, subsets of
APCs were isolated as in panel A and used (104 DCs and
3   105 lymphocytes) to stimulate OT-I (1.4   105) and
OT-II (2   105) cells. [3H]thymidine uptake was measured
at 38–50 h. (C) 20   106 EL-4 thymoma cells loaded with
OVA with 10 mg/ml OVA during osmotic shock were in-
jected. CD8  and CD8  CD11c  DCs and CD11c  cells
were prepared by MACS columns 8 h later and cultured
with 2   105 OT-I T cells in 96-well flat bottomed mi-
crotest plates in triplicates. 3H-TdR uptake between 36–
48 h was measured. Control mice were injected EL-4 cells
treated by the same way in the absence of OVA. Purities of
CD8  and CD8  DCs from the mice injected with OVA-
loaded EL-4 cells were 91.4 and 90.3%, respectively. (D)
TAP-dependent presentation of OVA by DCs to specific
CD8  OT-I T cells. CD11c  DCs were obtained from
the TAP /  and littermate control mice that had been in-
jected intravenously with 15   106 OVA-loaded or un-
loaded EL-4 cells 7.5 h before. Graded doses of DCs were
cultured with 1   105 OT-I T cells in round-bottomed
microculture plates for 48 h. 3H-TdR uptake for the last
8 h was determined.1299 Iyoda et al.
cells is also readily observed in DCs in splenic red pulp,
and by some macrophages in the marginal zone of tissue
sections of spleen (Fig. 4, G–I), as long as one looks within
1 h after injection of the apoptotic cells. However,
sialoadhesin  (CD169 ) large phagocytic cells are difficult
to liberate into a cell suspension. In contrast, marginal zone
and red pulp macrophages do not appear to participate in
the clearance of live allogeneic B cells, killed by NK cells
(Fig. 4, A–C).
A number of functional differences have been reported
in the function of CD8  and CD8  DCs from mice.
Shortman et al. first noted that CD8  DCs are less active in
inducing T cell proliferation and cytokine production (35–
37). In contrast, when DC subsets are pulsed with antigen
and matured ex vivo, and then reinjected into mice, CD8 
DCs preferentially stimulate strong Th1 responses (38, 39).
This paper describes a new functional distinction of the
CD8  subset that can be documented in situ and in cul-
ture. These DCs selectively take up dying cells under sev-
eral conditions. The first are syngeneic splenocytes ren-
dered apoptotic by osmotic shock before injection, a
procedure commonly used to study delivery of cell-associ-
ated proteins into mice (16–18). The second are intact allo-
geneic cells that are likely killed in vivo by asialoGM1 
NK cells. The third are cell lines and tumor cells induced
to apoptose by various means. The highest frequencies of
phagocytic CD8  DCs in vivo are observed with alloge-
neic cells, with 20–30% of the DCs showing uptake of the
injected CFSE-labeled allogeneic B cells. These findings
with CD8  DCs in mice parallel the findings of Huang et
al. who have reported that the subset of CD4  DCs in rat
mesenteric lymph selectively carries apoptotic fragments of
intestinal epithelial cells (40). CD8 is not expressed by rat
DCs, but the phagocytic CD8  mouse DCs are CD4 
(while CD8  DCs are to a major extent CD4  [26]), paral-
leling the data of Huang et al.
We suspect that the selective capacity of CD8  DCs to
cross present dying cells on MHC class I is controlled pri-
marily at the level of specific endocytic receptors, rather
than subsequent processing. Both subsets of DCs were able
to present soluble OVA to MHC class I–restricted T cells
(Fig. 8 B), which is distinct from the report of Pooley et al.
(41). They found that CD8  DCs selectively presented
soluble OVA on MHC class I, while CD8  DCs present
OVA on MHC class II. Perhaps there are quantitative dif-
ferences that we were unable to detect with our particular
preparation of OVA; also we did not add IL-2 to our T
cell assays. CD8  DCs do have phagocytic activity, as we
confirmed that both CD8  and CD8  DCs take up FITC
latex (20). CD8  DCs also selective take up and present
dying cells in vitro, where access of particles to both
CD8 CD8  DCs is ensured. Therefore CD8  DCs are
phagocytic and can present antigens on both MHC class I
and II; however, this DC subset seems to ignore dying
cells. We hypothesize that CD8  DCs selectively express a
receptor for apoptotic cells. This receptor is not the DEC-
205 receptor, at least exclusively. DEC-205 is abundant on
CD8  DCs (26, 27), but DEC-205 knockout mice are
comparably efficient to wild-type in taking up injected
cells (Fig. 5). An analysis of mRNA expression for several
candidate phagocytic receptors for dying cells (33, 34) only
identified CD36 as being expressed more abundantly in
CD8  DCs. Most other receptors were expressed similarly
in both DC subsets, or were more abundant in CD8  DCs
(Fig. 9).
It is of interest that several DC subsets are proving to have
distinct receptors for endocytosis. These include BDCA-2
on plasmacytoid DCs (42), Langerin on Langerhans cells
(43), DC-SIGN (44) and asialoglycoprotein receptor on
monocyte-derived DCs (45). This may allow subsets of
DCs to present select antigens and microbes; in addition
these subsets can express distinct toll-like receptors (46, 47).
The selective uptake of dying cells, which is evident in vivo
and at the single cell level, represents one of the most dra-
matic known differences in the function of CD8  and
CD8  DC subsets in mouse spleen and lymph node.
It is proposed (48–50) that the uptake of antigens by im-
mature DCs in the steady-state will lead to the induction of
tolerance to those peptides that are successfully presented,
whereas maturation stimuli are required to make DCs im-
munogenic for effector and memory cell formation. Evi-
Figure 9. RT-PCR analysis for the expression of receptors that may be
involved in engulfment of dying cells. Purified DC subsets from spleen,
obtained by FACS®-sorting, were subject to the assay and compared with
peritoneal macrophages.1300 Uptake of Dying Cells by CD8  DCs In Situ
dence for this has recently been obtained in studies of the
presentation of an antigenic peptide delivered selectively to
DCs in situ via a monoclonal anti–DEC-205 antibody (49).
There is evidence that certain necrotic cells, but not apop-
totic cells, are able to induce maturation of DCs in culture
(51, 52), with the release of heat shock proteins being a rel-
evant stimulus (53, 54). Experiments to test the tolerizing
and immunizing properties of cell-associated antigens, in-
jected under steady-state and DC maturation conditions,
are underway using the methods described here to facilitate
the uptake of dying cells by DCs in situ.
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